Nexium Capsules LDA Specific Clinical Experience Investigation
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Nexium Capsules Specific Clinical Experience Investigation for Long-term Use Concerning Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer With LDA|
- Adverse events incidence [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]Number of Adverse Drug Reactions
- Non-recurrence rate of peptic ulcer [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||January 2017|
|Estimated Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01729182
|Contact: AstraZeneca Clinical Study Informationemail@example.com|
|Contact: AstraZeneca Information (Outside US)||0018002369933|
Show 117 Study Locations
|Study Director:||Shigeru Yoshida, MD||Astrazeneca K.K.|